Disc Medicine, Inc. (NASDAQ: IRON) announced on October 21, 2025 that it has priced an upsized underwritten offering of 2,619,049 shares of common stock and 59,523 pre‑funded warrants to purchase shares of its common stock. The shares are priced at $84.00 each and the pre‑funded warrants at $83.9999, with an aggregate gross proceeds of approximately $225 million. The offering is expected to close on October 22, 2025, subject to customary closing conditions.
The company will use the net proceeds to support the potential commercialization of its lead asset, bitopertin, for erythropoietic protoporphyria (EPP) and X‑linked protoporphyria (XLP), to fund research and clinical development of its current and additional product candidates, and for working capital and other general corporate purposes. This financing is intended to extend the company’s cash runway through 2028 and to de‑risk near‑term operations.
The offering is being led by Jefferies, Leerink Partners, Morgan Stanley and Cantor as joint book‑running managers, with Wedbush PacGrow and H.C. Wainwright & Co. acting as co‑managers. AI DMI LLC, the selling stockholder, is selling 297,619 shares of common stock in the offering and has granted the underwriters a 30‑day option to purchase up to an additional 446,428 shares at the public offering price. The pre‑funded warrants allow investors to purchase shares at a nominal exercise price of $0.0001 per share.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.